2026-04-18T13:52:35Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/164562024-09-27T08:11:45Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Madel, Maria-Bernadette author Halper, Julia author Ibáñez, Lidia author Claire, Lozano author Rouleau, Matthieu author Boutin, Antoine author Mahler, Adrien author Pontier-Bres, Rodolphe author Ciucci, Thomas author Topi, Majlinda author Hue, Christophe author Amiaud, Jerome author Iborra, Salvador author Sancho, David author Heymann, Dominique author Garchon, Henri-Jean author Czerucka, Dorota author Apparailly, Florence author Duroux-Richard, Isabelle author Wakkach, Abdelilah author Blin-Wakkach, Claudine author 2023-02-27 Bone destruction is a hallmark of chronic inflammation, and bone-resorbing osteoclasts arising under such a condition differ from steady-state ones. However, osteoclast diversity remains poorly explored. Here, we combined transcriptomic profiling, differentiation assays and in vivo analysis in mouse to decipher specific traits for inflammatory and steady-state osteoclasts. We identified and validated the pattern-recognition receptors (PRR) Tlr2, Dectin-1, and Mincle, all involved in yeast recognition as major regulators of inflammatory osteoclasts. We showed that administration of the yeast probiotic Saccharomyces boulardii CNCM I-745 (Sb) in vivo reduced bone loss in ovariectomized but not sham mice by reducing inflammatory osteoclastogenesis. This beneficial impact of Sb is mediated by the regulation of the inflammatory environment required for the generation of inflammatory osteoclasts. We also showed that Sb derivatives as well as agonists of Tlr2, Dectin-1, and Mincle specifically inhibited directly the differentiation of inflammatory but not steady-state osteoclasts in vitro. These findings demonstrate a preferential use of the PRR-associated costimulatory differentiation pathway by inflammatory osteoclasts, thus enabling their specific inhibition, which opens new therapeutic perspectives for inflammatory bone loss. Elife. 2023 Feb 27;12:e82037. http://hdl.handle.net/20.500.12105/16456 36848406 10.7554/eLife.82037 2050-084X eLife Specific targeting of inflammatory osteoclastogenesis by the probiotic yeast S. boulardii CNCM I-745 reduces bone loss in osteoporosis.